- Current report filing (8-K)
11 March 2010 - 2:00AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
March
4
, 2010
SHENGTAI PHAR
MACEUTICAL
, INC.
(Exact name of registrant as specified
in its charter)
|
Delaware
(State
or other jurisdiction of
incorporation)
|
000-51312
(Commission
File
Number)
|
54-2155579
(IRS
Employer
Identification
No.)
|
|
Changda
Road East
Development
District, Changle County
Shandong, PRC
(Address
of principal executive offices)
|
262400
(Zip
Code)
|
Registrant
’
s telephone number, including area code:
011-86-536-6295802
Copies
to:
Benjamin Tan, Esq.
Sichenzia Ross Friedman Ference
LLP
61 Broadway, 32 Flo
or
New York, New York
10006
Phone:
(212) 930-9700
Fax: (212) 930-9725
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General I
nstruction A.2.
below):
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant
to
Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
On March
4, 2010, the Company issued a press release annexed hereto as Exhibit 99.1.
The
information in this report, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “
Exchange Act
”), or
incorporated subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended (the “
Securities Act
”), and
shall not be incorporated by reference in any registration statement or other
document filed under the Securities Act or the Exchange Act, whether made before
or after the date hereof, regardless of any general incorporation language in
such filings, except as shall be expressly set forth by specific reference in
such a filing.
|
Item 9.01.
|
Financial Statements and
Exhibits.
|
|
|
|
|
|
|
99.1
|
Press
Release dated March 4, 2010, issued by Shengtai Pharmaceutical,
Inc.
|
SIGNATURES
Pursuant to the requirements of the
Securities and Exchange Act of 1934, the registrant has duly caused this report
to be signed on its b
ehalf
by the undersigned hereunto duly authorized.
|
|
SHENGTAI
PHARMACEUTICAL
,
INC.
|
|
|
|
|
|
|
Dated:
March
10
, 2010
|
|
|
|
|
By:
|
/s/Qingtai
Liu
|
|
|
|
Name:
Qingtai Liu
|
|
|
|
Title:
Chief
Executive
Officer
|
|
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Jul 2023 to Jul 2024
